{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T04:35:49Z","timestamp":1792989349500,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jchf.2021.06.017","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T03:06:53Z","timestamp":1629688013000},"page":"807-820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart\u00a0Failure"],"prefix":"10.1016","volume":"9","author":[{"given":"John J.V.","family":"McMurray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bergur V.","family":"Stef\u00e1nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Jongs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douwe","family":"Postmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Correa-Rotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn M.","family":"Chertow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan Fan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. David","family":"Sj\u00f6str\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Toto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Langkilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2021.06.017_bib1","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.semnephrol.2018.08.005","article-title":"Heart failure in end-stage kidney disease: pathophysiology, diagnosis, and therapeutic strategies","volume":"38","author":"Rangaswami","year":"2018","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.jchf.2021.06.017_bib2","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","article-title":"Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"House","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.jchf.2021.06.017_bib3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/MNH.0000000000000497","article-title":"Updates in the management of heart failure for the chronic kidney disease patient","volume":"28","author":"Hsu","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.jchf.2021.06.017_bib4","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1681\/ASN.2006101159","article-title":"Reduced kidney function as a risk factor for incident heart failure: the Atherosclerosis Risk In Communities (ARIC) study","volume":"18","author":"Kottgen","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jchf.2021.06.017_bib5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/jamacardio.2016.4652","article-title":"Absolute rates of heart failure, coronary heart disease, and stroke in chronic kidney disease: an analysis of 3 community-based cohort studies","volume":"2","author":"Bansal","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"1 Suppl 1","key":"10.1016\/j.jchf.2021.06.017_bib6","first-page":"A6","article-title":"US Renal Data System 2019 annual data report: epidemiology of kidney disease in the United States","volume":"75","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jchf.2021.06.017_bib7","first-page":"8","article-title":"Chronic kidney disease and heart failure\u2014bidirectional close link and common therapeutic goal","volume":"57","author":"Shiba","year":"2011","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.jchf.2021.06.017_bib8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.06.017_bib9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.06.017_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.06.017_bib11","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.06.017_bib12","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.06.017_bib13","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.06.017_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ahj.2020.12.008","article-title":"Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: results from the CREDENCE trial","volume":"233","author":"Sarraju","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2021.06.017_bib15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.120.051675","article-title":"Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2021.06.017_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.06.017_bib17","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2213-8587(14)70031-2","article-title":"Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored","volume":"2","author":"McMurray","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jchf.2021.06.017_bib18","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jacc.2020.01.017","article-title":"Is heart failure still the frequent, forgotten, and often fatal complication of diabetes?","volume":"75","author":"Alexander","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2021.06.017_bib19","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"}],"updated-by":[{"DOI":"10.1016\/j.jchf.2022.04.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000}}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177921003346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177921003346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T14:58:53Z","timestamp":1658242733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177921003346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2213177921003346"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2021.06.017","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740686798.793590320","asserted-by":"object"}]},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart\u00a0Failure","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2021.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}